Bladder Cancer
Ellinger J, El Kassem N, Heukamp LC, Matthews S, Cubukluoz F, Kahl P, Perabo FG, Müller SC, von Ruecker A, Bastian PJ.
Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer.
J Urol. 2008;179(1):346-52.
Marsit CJ, Houseman EA, Schned AR, Karagas MR, Kelsey KT.
Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer.
Carcinogenesis. 2007;28(8):1745-51.
Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, Hamdy FC, Catto JW.
Promoter hypermethylation identifies progression risk in bladder cancer.
Clin Cancer Res. 2007;13(7):2046-53.
Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, Westra WH, Schoenberg M, Zahurak M, Goodman SN, Sidransky D.
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
J Natl Cancer Inst. 2006;98(14):996-1004.
Additional Publications
Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P.
Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel.
Clin Cancer Res. 2004;10(6):1887-93.
Chan MW, Chan LW, Tang NL, Lo KW, Tong JH, Chan AW, Cheung HY, Wong WS, Chan PS, Lai FM, To KF.
Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.
Int J Cancer. 2003;104(5):611-6.
Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF.
Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features.
Cancer Res. 2001;61(24):8659-63.
Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H, Tanaka Y, Kikuno N, Nakagawa M, Igawa M, Dahiya R.
Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
Clin Cancer Res. 2006;12(7 Pt 1):2109-16.
Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Miller K, Schrader M.
Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Int J Cancer. 2006; [Epub ahead of print]
Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC, Catto JW.
Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls.
Oncogene. 2006;25(13):1984-8.
Marsit CJ, Karagas MR, Danaee H, Liu M, Andrew A, Schned A, Nelson HH, Kelsey KT.
Carcinogen exposure and gene promoter hypermethylation in bladder cancer.
Carcinogenesis. 2006;27(1):112-116. Epub 2005 Jun 29.
Wolff EM, Liang G, Jones PA.
Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.
Nat Clin Pract Urol. 2005 (10):502-10. Review.
Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, Li QL, Yang JO, Ito Y, Bae SC
RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.
Cancer Res. 2005;65(20):9347-54.
Sathyanarayana UG, Maruyama R, Padar A, Suzuki M, Bondaruk J, Sagalowsky A, Minna JD, Frenkel EP, Grossman HB, Czerniak B, Gazdar AF.
Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes.
Cancer Res. 2004;64(4):1425-30.
Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, Cheung HY, Wong WS, Chan PS, Lai FM, To KF.
Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients.
Clin Cancer Res. 2002;8(2):464-70.